RESUMEN
We have recently shown in Liver Clinic patients that saliva instead of serum may be used for anti-HCV detection. As compared to blood withdrawing, saliva is easier to obtain, non invasive, especially for infants. In the present study, sequential determination of serum and salivary anti-HCV was performed in the same cohort for 36 months. Anti-HCV seropositive and seronegative patients were studied. Blood and saliva samples were obtained simultaneously. From the anti-HCV seronegative patients (n=33), 161 sequential serum and 161 matched saliva samples were obtained. All were anti-HCV negative. From the anti-HCV seropositive patients (n=35), 131 sequential serum and 131 matched saliva samples were obtained. All sequential serum samples were anti-HCV positive. Of the saliva samples 126 (96%) were anti-HCV positive and five (4%) were anti-HCV negative. These five samples were obtained from two patients with autoimmune hepatitis and HCV-RNA seronegative by PCR. The results suggest that saliva may serve as a substitute for serum for the detection of anti-HCV antibodies.
Asunto(s)
Anticuerpos Antivirales/análisis , Hepacivirus/inmunología , Hepatopatías/virología , Saliva/inmunología , Estudios de Cohortes , Estudios de Seguimiento , Hepacivirus/genética , Hepatitis C/diagnóstico , Humanos , ARN Viral/análisis , Saliva/virologíaRESUMEN
Infection with hepatitis C virus (HCV) is usually established by detection of serum antibodies (anti-HCV). This study was conducted in order to evaluate whether saliva and urine may substitute serum for anti-HCV detection. Serum, saliva, and urine were obtained simultaneously from 141 patients with a variety of liver diseases and from 52 patients with autoimmune diseases (systemic lupus erythematosus n = 27 and rheumatoid arthritis n = 25). The cell free fraction of saliva and urine samples was tested for anti-HCV using a modification of a serum anti-HCV kit. Western blot analysis was used as a confirmation method. Of the patients with liver diseases, 73 were anti-HCV-seropositive. Salivary and urinary anti-HCV could be detected in 66 (90%) and 36 (49%) of the anti-HCV-seropositive patients, respectively. The presence of anti-HCV in saliva or urine was not related to the severity of liver disease. All the anti-HCV-seronegative liver patients were negative for salivary anti-HCV and 22 (32%) had urinary anti-HCV. The patients with autoimmune diseases were all anti-HCV-seronegative. None had detectable salivary anti-HCV while 33 (63%) were positive for urinary anti-HCV. Western Blot analysis confirmed the presence of anti-HCV in all serum and saliva samples tested but only in 2/12 urine samples. The results suggest that saliva, but not urine, may serve as a substitute for serum for the determination of anti-HCV positivity.
Asunto(s)
Anticuerpos contra la Hepatitis C/orina , Hepatitis C/orina , Saliva/virología , Western Blotting , Hepatitis C/virología , Anticuerpos contra la Hepatitis C/inmunología , Humanos , Técnicas para Inmunoenzimas , Saliva/inmunologíaRESUMEN
OBJECTIVE: We evaluated the significance of IgA antibodies directed against the hepatitis B virus core antigen (IgA anti-HBc) as a marker for viral replication. STUDY DESIGN/METHODS: Serum samples of 143 hepatitis B surface antigen (HBsAg) carriers and 189 HBsAg-negative subjects were studied. Hepatitis B virus (HBV) DNA was detected by polymerase chain reaction. IgA anti-HBc was determined by a capture enzyme-linked immunosorbent assay developed in our laboratory. The results were compared with those for IgM anti-HBc, which were determined by a commercially available method. RESULTS: IgA anti-HBc was detected in 57 (40%) and HBV DNA in 38 (27%) of the HBsAg carriers. Among the HBsAg-negative subjects, IgA anti-HBc and HBV DNA were detected simultaneously in four samples. All 42 HBV DNA-positive samples were IgA anti-HBc positive. IgM anti-HBc was detected in 27 (64%) of them. CONCLUSIONS: IgA anti-HBc is a sensitive marker for HBV replication, and its absence may exclude HBV replication. The role of IgA anti-HBc in monitoring response to therapy and predicting clinical course is being evaluated.
Asunto(s)
ADN Viral/sangre , Anticuerpos contra la Hepatitis B/análisis , Antígenos de Superficie de la Hepatitis B/inmunología , Virus de la Hepatitis B/inmunología , Inmunoglobulina A/análisis , Inmunoglobulina M/análisis , Biomarcadores , Portador Sano , Ensayo de Inmunoadsorción Enzimática , Femenino , Anticuerpos contra la Hepatitis B/inmunología , Virus de la Hepatitis B/fisiología , Virus de la Hepatitis Delta/inmunología , Humanos , Inmunoglobulina A/inmunología , Inmunoglobulina M/inmunología , Masculino , Persona de Mediana Edad , Estudios Seroepidemiológicos , Replicación ViralRESUMEN
The significance of chlamydia serum IgG and IgA antibodies was studied, by immunoperoxidase assay, in 210 homosexual men at various stages of HIV infection. Cross sectional analysis of chlamydia IgG antibodies at a titer of > or = 128 indicated a significantly higher prevalence rate among AIDS patients (27.0%) as compared to asymptomatic HIV seronegatives (6.0%) (p = 0.022). The geometric mean titer (GMT) of IgG antibodies to chlamydia was also significantly higher in AIDS patients (106.4) as compared to HIV seronegatives (58.2) (p = 0.022) and persistently asymptomatic HIV seropositives (51.7) (p = 0.05). Chlamydia IgA antibodies did not differ significantly in prevalence and GMT among the various groups.